Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year period
GAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net Income of $181 million
Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $986 million, including an $81 million acquired In-Process Research & Development ("IPR&D") charge, up 8% on a Reported basis over the prior year period
BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2025 RESULTS
Delivered tenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA (non-GAAP)1 growth, with 7% Reported and 5% Organic (non-GAAP)1 Revenue growth, and 7% Adjusted EBITDA (non-GAAP)1 growth, including an $81 million charge for acquired IPR&D
Raising full-year 2025 Revenue, Adjusted EBITDA (non-GAAP)1, and Adjusted Cash Flow from Operations (non-GAAP)1 guidance
Completed acquisition of DURECT Corporation, expanding Bausch Health's hepatology portfolio with addition of lead asset, Larsucosterol, a novel epigenetic modulator with FDA Breakthrough Therapy Designation for treatment of alcohol-associated hepatitis ("AH")
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.